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ABSTRACT 
Objective: Despite growing evidence in the field of cognitive function in mood disorders, the 
neurocognitive profiles of patients with unipolar and bipolar depression still need further 
characterization. In this study, we applied network analysis, hypothesizing this approach could 
highlight differences between Major Depressive Disorder (MDD) and Bipolar Disorder (BD) from a 
cognitive perspective. 
Methods: The cognitive performance of 109 patients (72 unipolar and 37 bipolar depressed 
outpatients) was assessed through the Montreal Cognitive Assessment (MoCA) and a series of 
clinical variables was collected. Differences in cognitive performance between MDD and BD 
patients were tested using non parametric tests. Moreover, a network graph representing MoCA 
domains as nodes and Spearman’s rho correlation coefficients between the domains as edges was 
constructed for each group. 
Results: The presence of mild cognitive impairment was observed both in MDD and BD patients 
during depression. No statistical significant difference was found between the two groups in terms 
of overall cognitive performance and across single domains. Nonetheless, network analytic metrics 
demonstrated different roles of memory and executive dysfunction in MDD vs BD patients: in 
particular, MDD network was more densely interconnected than BD network and memory was the 
node with the highest betweenness and closeness centrality in MDD, while executive function was 
more central in BD.  
Conclusions: From a network analytic perspective, memory impairment displays a central role in 
the cognitive impairment of patients with unipolar depression, whereas executive dysfunction 
appears to be more central in bipolar depression. Further research is warranted to confirm our 
results. 
 
Keywords: cognitive impairment, network analysis, bipolar disorder, major depressive disorder, 
acute depression, remission. 
 
Introduction 
Cognitive impairment is one of the most important psychopathological features in both major 
depressive disorder (MDD) and bipolar disorder (BD), particularly during major depressive 
episodes (MDE). Over the last few decades, the number of studies addressing neurocognitive 
functioning in mood disorders has grown exponentially1, with increasing scientific interest about 
the influence of cognitive impairment on the course of these disorders2,3, determining a more severe 
impairment of global functioning and a higher degree of overall disability4–8. Furthermore, 
cognitive impairment is currently considered a crucial therapeutic target in depression, in order to 
achieve cognitive remission9 and recovery10. 
From a cognitive perspective, many studies have demonstrated that depressed patients exhibit a 
wide range of cognitive deficits both in MDD and BD. These deficits do not necessarily depend on 
the mood state11,12 and mainly regard the domains of memory13–18, attention14,19–21,  executive 
functions22–25 and language26. 
However, few studies have directly compared the cognitive profiles of patients with MDD and 
BD18. In addition, these studies included patients regardless of illness phase and produced 
conflicting evidence, showing, in some cases, different cognitive alteration profiles between 
unipolar and bipolar patients (both in terms of expression and severity), and overlapping deficits in 
other cases27. For instance, in a study comparing three groups of patients with MDD, BD-I and BD-
II, Xu and colleagues (2012) found similar patterns of cognitive dysfunction during acute 
depression across the 3 groups, but observed a globally greater cognitive impairment in BD-I 
 compared to BD-II and MDD27. Daniel and co-workers (2013) confirmed that both patients with 
MDD and BD-I showed some cognitive deficits in relation to information processing speed 
compared to healthy controls, but they could not find any specific difference between the two 
subtypes of mood disorder28. Moreover, overlapping alterations in bipolar and unipolar patients 
were observed by Hermens et al. (2010)29. Finally, while some authors have shown greater 
deficiency in executive functions in bipolar versus unipolar patients30, at least one study has not 
shown significant differences in this domain31. Indeed, in literature there is also evidence for a 
higher degree of cognitive impairment in unipolar compared to bipolar depression, regarding 
memory, executive functions and decision-making32, as well as executive functions and 
psychomotor speed in drug-naive patients33. 
Based on the above, to date, the presence of distinctive profiles between unipolar and bipolar 
depression from a cognitive perspective is still debated. In clinical settings, however, that would 
add useful elements to the differential diagnosis between these two nosographic entities, which are 
often confused and misdiagnosed34. Currently, the elements considered suggestive of bipolarity 
during depression are mainly represented by psychopathological symptoms and clinical variables 
(such as the presence of irritability, psychomotor agitation, emotional lability, rapid thoughts, 
psychotic symptoms, atypical depressive symptoms including hypersomnia and hyperphagia)34,35, 
but do not comprise any cognitive specifier. 
The limited evidence about the distinctive characteristics of cognition in MDD and BD may 
actually reflect the presence of methodological biases of the aforementioned studies (above all, the 
enrollment of patients during different phases of illness) and the lack of sensitivity of classical 
statistical methods in the analysis of potential differences.  
For these reasons, in the present study, the problem of the differential diagnosis between the 
cognitive profiles of unipolar and bipolar depression was addressed by conducting a network 
analysis, an innovative analytical model that is gaining growing interest in the study of 
psychopathology. Thus, our main objective was to evaluate the differences between the cognitive 
profiles of patients with MDD and BD during depression, by performing a network analysis of the 
cognitive domains of the Montreal Cognitive Assessment (MoCA)36. A secondary objective was to 
confirm the usefulness of the MoCA as a cognitive screening tool in depression, and then after 
remission, by estimating the rate and severity of cognitive impairment in a naturalistic sample of 
depressed outpatients. 
 
Methods 
Eligibility for the study 
The present study had a prospective, observational design and it was conducted in a naturalistic   
setting, namely the Centre for the Diagnosis and Treatment of Depressive Disorders (CTDD) of the 
ASST Fatebenefratelli-Sacco in Milan, an outpatient, tertiary psychiatric service dedicated to the 
treatment of affective disorders. Both outpatients and patients undergoing day-hospital care between 
January 2016 and December 2017 were considered eligible.  
The design of this study fitted most of the methodological criteria defined by the International 
Society for Bipolar Disorders (ISBD) task force, as stated in the guidelines for the study of 
cognitive disorders in BD37, as well as those previously proposed by Burdick and colleagues 
(2015)38, although it was conceived before their publication. 
Both subjects of male and female gender, above the age of 18, with a current diagnosis of MDE 
within MDD, BD-I or BD-II were considered eligible for the study. Diagnoses were formulated 
through a structured clinical interview complying with the criteria of the Diagnostic and Statistical 
Manual of Mental Disorders-Fifth Edition (DSM-5)39. Inclusion and exclusion criteria are 
summarized in table 1. 
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The main demographic and clinical characteristics of the sample were collected in an electronic 
database through a retrospective chart review, both in traditional records and computerized form or, 
when necessary, through a direct interview with the subject enrolled in the study. 
All subjects enrolled in the study provided informed consent to the collection of personal and 
sensitive data, as well as the consent to undergo the psychometric evaluation and cognitive test 
described below. 
 
Psychopathological assessment 
The severity of depressive symptomatology was assessed with the 21 items-Hamilton Depression 
Rating Scale (HDRS)40 at the time of entry into the study (depressive phase) and at clinical 
remission (remission, defined as a HDRS total score of less than 8 according to literature). In 
addition, at the time of entry into the study (depression) and at remission (remission), the severity of 
the anxious component was assessed with the Hamilton Anxiety Rating Scale (HARS)41. Clinical 
remission was considered complete upon the achievement of a concomitant score of HDRS<8 and 
HARS<7. 
 
Cognitive screening: the Montreal Cognitive Assessment (MoCA) 
In this study, cognitive performance was assessed with the Montreal Cognitive Assessment 
(MoCA), administered during the depressive phase and after clinical remission (as defined above). 
The MoCA is a short screening tool developed by Nasreddine et al. (2005) for the identification of 
mild cognitive impairment (MCI), a clinical condition of increased risk for the subsequent 
development of Alzheimer's disease or other forms of dementia36. 
The MoCA examines six different cognitive domains: executive functions, visuospatial abilities, 
attention, verbal fluency, memory and spatio-temporal orientation. Through the measurement of 
different cognitive domains, the total score of the MoCA, which varies from a minimum of 0 to a 
maximum of 30, provides a global assessment of the cognitive performance of the subject. In 
relation to the years of educations, a score equal to or above 26 is considered normal36, and a 
supplementary point is added if years of education are less than 12. The average time to administer 
the test is usually around 10-15 minutes. 
The MoCA has good internal consistency with a Cronbach's alpha value of 0.8336. Furthermore, the 
sensitivity and the specificity of the MoCA in identifying MCI are 90% and 87%, respectively. 
Finally, the positive (VPP) and negative (VPN) predictive value of the MoCA are 89% and 91% for 
MCI [40]. 
Among cognitive screening tests, the Mini Mental State Examination (MMSE)42 is the most 
commonly used for the detection of cognitive impairment. However, the MMSE is considered less 
sensitive in detecting deficits in executive functions, attention and visuospatial domains36,43. 
Compared to the MMSE, the MoCA includes several tasks specifically aimed at evaluating 
executive functions, attention44 and memory. 
The MoCA has proven to be a sensitive tool for screening patients with other forms of dementia, 
like, for instance, vascular dementia45, dementia associated with Parkinson's disease46 and finally 
Frontotemporal Dementia47. With respect to psychiatric disorders, the MoCA has been used 
successfully to evaluate cognitive impairment in patients with depression, BD and schizophrenia48,49 
as well as in depressed patients undergoing electroconvulsive therapy (ECT)50. 
 
Statistical analysis 
The Kolmogorov-Smirnov and Shapiro-Wilk tests were performed to test the assumption of normal 
distribution of the clinical and sociodemographic variables, as well as that of HDRS, HARS and 
MoCA scores.  
 In MDD, with the exception of age, D(61)=0.074, p=0.200, HDRS score in the depressive phase, 
D(61)=0.078, p=0.200, and HARS score in the depressive phase, D(61)=0.071, p=0.200,  data 
regarding all other variables violated the assumption of normal distribution.  
In BD, a normal distribution was found for age, D(33)=0.100, p=0.200, age of onset, D(33)=0.111, 
p=0.200, MoCA score in depressive phase, D(33)=0.142, p=0.087, HDRS score in the depressive 
phase, D(33)=0.090, p=0.200, HARS score in the depressive phase, D(33)=0.127, p=0.195, and 
HDRS score in clinical remission phase, D(33)=0.128,  p=0.186. Data regarding all other socio-
demographic and clinical variables violated the assumption of normal distribution.. Thus, based on 
these preliminary analyses, non-parametric tests were used for the statistical analyses described 
below. 
Demographic and clinical characteristics were compared between the two groups using Mann-
Whitney U non-parametric test for continuous variables and Chi-square (χ2) test for dichotomous 
variables. 
Then, Mann-Whitney U test was used to analyse the differences between the scores of the single 
cognitive domains of the MoCA between the two groups and between the total scores of the scales 
for depression and anxiety. These analyses were conducted for both the depressive and remission-
related scores. Furthermore, the statistical significance of the change of the MoCA total scores and 
of the individual cognitive domains from the depressive phase to clinical remission was calculated 
using the Wilcoxon signed-rank test. 
For the two groups of patients with MDD and BD, the matrix of Spearman rho (ρ) correlation 
coefficients between the six MoCA domains (memory, executive functions, verbal fluency, 
orientation, attention, visuospatial abilities) was calculated.  
In addition, for each of the two groups examined, we constructed a network graph in which the 
nodes represent the six cognitive domains of the MoCA and the edges represent Spearman’s rho 
correlation coefficients between the domains. The cognitive networks for unipolar and bipolar 
depression were thus constructed. Within both networks, only the connections corresponding to a 
coefficient ρ≥0.20 were represented. Furthermore, in order to allow an immediate graphical 
comparison, the nodes within the networks have been arranged using a circular layout. 
Finally, through a network analysis, for each network we calculated three metrics defined as 
follows: 
 Network density: corresponding to the average of the correlation coefficients, network 
density expresses the degree of intercorrelation between the symptoms of a network, and 
therefore their tendency to present themselves simultaneously51; 
 Closeness centrality: a parameter indicating how easily all the other nodes of a network can 
be reached starting from the node examined, that is the average distance of that node from 
all the others. The nodes with the highest closeness quickly affect the other nodes and they 
are more influenced by the other nodes52,53; 
 Betweenness centrality: it expresses the number of times a node is involved in the shortest 
path length between two other nodes. The nodes with a high betweenness are those that 
facilitate connections within a network52,53. 
For all the analyses, the level of statistical significance was defined as p <0.05. Statistical analyses 
were performed using IBM SPSS version 22.0, while network analysis and the construction of the 
network graph were obtained using R54 and Cytoscape version 3.2.155. 
 
Results 
Sample characteristics 
A total of 109 outpatients with a MDE was enrolled in the study: 72 patients (66.1%) diagnosed 
with MDD and 37 patients (33.9%) diagnosed with BD. The two groups of patients were 
homogeneous with regard to most of the main demographic and clinical variables (see table 2).  
The two groups significantly differed with regard to previous hospitalizations (χ2=14.924, p<0.001), 
previous suicide attempts (χ2=4.688, p=0.030) and number of mood episodes (U=566.0, Z =-4.028, 
p<0.001). Moreover, some differences emerged in terms of current medication status, as patients 
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with BD were more frequently treated with antipsychotics (χ2=5.541, p=0.019) and mood stabilizers 
(χ2=23.096, p<0.001), but less frequently with antidepressants (χ2=8.224, p=0.004) compared to 
patients with MDD. However, there was no difference in treatment with benzodiazepines (χ2=1.097, 
p=0.295). The aforementioned differences likely reflected the naturalistic context in which the 
study was conducted because, in clinical practice, MDD and BD are characterized by a different 
course of illness and by different treatment strategies. We took into consideration these differences 
by conducting some analyses to weight their impact on the variables examined in the present study. 
During depression, mean HDRS score and mean HARS were respectively 27.35±6.05 and 
21.61±9.062 for MDD, and 26.62±6.45 and 18.68±7.32 for BD. Therefore, the study sample 
presented with moderate to severe depressive symptomatology and with mild to moderate anxious 
symptomatology, as expected from the recruitment in a day-hospital service that is specifically 
dedicated to the treatment of severe forms of depression. No statistically significant differences 
emerged between the two groups with respect to depressive symptomatology (U=1265.5, Z=-0.311, 
p=0.756) nor with respect to anxious symptomatology (U=1054.5, Z=-1.557, p=0.115). 
 
Cognitive performance during depression 
The mean MoCA total score (adjusted for education level) in the entire sample was 24.04± 3.94, 
lower than the normality cut-off of 26, as defined by the normative studies of the test. Globally, 
55.9% of the subjects enrolled for the study had mild cognitive impairment, defined as a MoCA 
score of less than 26. In the two groups, 54.2% of patients with MDD and 59.4% of patients with 
BD had cognitive impairment, with a mean MoCA score of 24.11±4.04 and 23.89±3.78 
respectively, and no statistically significant difference between them (U=1274.0, Z=-0.373, 
p=0.709).  
Analysing the single cognitive domains of the MoCA, the total score of the memory domain was 
respectively 2.35±1.71 and 2.32±1.58 for MDD and BD, with no statistically significant differences 
between the two groups (U=1313.0, Z=- 0.124, p=0.902). 
During depression, no statistically significant difference emerged between unipolar and bipolar 
patients, even considering single domains, as shown in table 3. 
 
Cognitive performance after clinical remission 
On average, MDD and BD patients achieved remission after 77.43±34.85 days and 84.32±37.84 
days respectively, with no statsstically significant difference between the two groups (U=1195.5, 
Z=- 0.875, p=0.382). At time of clinical remission, the mean MoCA total score in the sample was 
25.94±2.60. In patients diagnosed with MDD the mean score was 25.81±2.65, while it was 
26.22±2.50 in patients with BD. Therefore, once remitted, patients with MDD remained on average 
below MoCA threshold of normality, whereas patients with BD achieved normal levels. Anyway, 
this difference was not statistically significant (U=1188.0, Z=-0.930, p=0.353). Analysing the single 
cognitive domains of the MoCA, there were no statistically significant differences between the two 
groups in any cognitive domain: Memory (U=1301.0, Z=- 0.206, p=0.837), Visuospatial skills 
(U=1241.5, Z =-0.608, p=0.543), Executive Functions (U=1249.5, Z=-0.611, p=0.541), Attention 
(U=1319.0, Z=-0.115, p=0.908), Verbal Fluency (U=1255.5, Z=-0.540, p=0.589), Orientation 
(U=1250.0, Z=-0.855, p=0.393). 
 
Change in cognitive performance between depression and remission 
All subjects enrolled in the study showed improvement in overall cognitive performance between 
depression and remission. There was indeed a statistically significant change in MoCA score both 
in the group of patients with MDD (Z=-7.326, p<0.001) and in the group of patients with BD 
(Z=3.773, p<0.001). 
Taking into consideration the single MoCA domains separately, in MDD patients there was a 
statistically significant improvement in the domains of Memory (Z=-4.273, p<0.001), Executive 
 Functions (Z=-3.431, p=0.001) and Attention (Z=-2.389, p=0.017), while there was no statistically 
significant variation in the domains of Visuospatial Abilities (Z = -0.576, p = 0.564), Verbal 
Fluency (Z=-1.531, p=0.126) and Orientation (Z=-0.401, p=0.688). 
Likewise, in BD, there was a statistically significant variation in Memory (Z=-3.559, p<0.001), 
Executive Functions (Z=-3.431, p=0.001) and Attention (Z=-2.234, p=0.020), while no significant 
changes were found in any other domain: Visuospatial Abilities (Z=-0.530, p=0.596), Verbal 
Fluency (Z=-1.554, p=0.120) and Orientation (Z=-1.734, p=0.083). 
 
Correlations between MoCA domains 
We calculated the matrix of Spearman’s rho (ρ) correlation coefficients (given the non-parametric 
distribution of the variables) among the scores of the six MoCA domains, both for MDD and for 
BD patients (see table 5).  
In patients with unipolar depression, 11 of the 14 correlation coefficients between cognitive 
domains were statistically significant. In the bipolar group, a lower proportion of statistically 
significant correlations emerged compared to unipolar patients (8 out of 15). After transforming 
MoCA single domains score into z scores and calculating Spearman's ρ correlations between them, 
no statistical significant differences emerged between the single domains correlations in MDD and 
BD patients. 
 
Network analysis of MoCA domains 
As described in the "Methods" section, the matrix of intercorrelations between the domains of the 
MoCA was used to construct a network graph for unipolar depression and one for bipolar 
depression. The two graphs are shown in Figures 1 and 2: the six nodes represent the domains of the 
MoCA, while the edges express the correlation existing between the two domains they connect. The 
higher the correlation value the thicker the line connecting the nodes. Within the networks, only 
moderate to strong correlations were expressed (ρ>0.20). 
The number of edges differed between the two networks: in fact, there were 13 edges in the network 
of unipolar depression and 10 in that of bipolar depression. 
As previously described, three statistical parameters were calculated for each of the two networks: 
density, betweenness centrality and closeness centrality. The so-called "network density" is 
mathematically corresponding to the average of the correlation coefficients between the domains. 
High density can be clinically interpreted as the patients’ tendency to have homogeneous patterns of 
cognitive impairment, affecting multiple domains at the same time, because if the density is higher, 
a patient developing deficits in one single domain is more likely to develop deficits in the other 
domains. In our study, the network of patients with unipolar depression had a higher density 
(ρ=0.34±0.13; 95% CI:0.26-0.41) than the network of patients with bipolar depression 
(ρ=0.29±0.12; 95% CI: 0.17-0.41).  
In Table 5, cognitive domains with the highest closeness centrality and betweenness centrality are 
reported. These two metrics can be calculated for each node of the network and, with different 
meanings, they express the specific role of that node within the network of symptoms. 
As described in the section on statistical analysis, closeness centrality is a parameter that expresses 
the ease with which all the other nodes of a network can be reached from the node examined, that is 
the average distance of that node from all the others. The betweenness centrality, on the other hand, 
expresses the number of times a node is involved in the shortest passage (or shortest path length) 
between two other nodes. The nodes with a high betweenness are those that facilitate connections 
within the network, while those with the highest closeness affect the other nodes faster and they are 
in turn more influenced by the other nodes52,53. 
In the unipolar depression network, the domain with the highest closeness and betweenness was 
Memory, followed by the domains of Executive Functions and Attention, respectively. 
On the other hand, in the network of bipolar depression, the domain of Executive Functions was the 
one with the highest closeness and betweenness, followed by the Attention. Verbal fluency was the 
third domain for betweenness, while Memory and Visuospatial Skills were third in closeness. 
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Discussion 
To our knowledge, this is the first study investigating the distinctive features of unipolar and bipolar 
depression from a cognitive perspective, through the application of an innovative statistical 
approach, such as the network analysis. Until now, research implementing network analysis in 
psychiatry has mainly focused on the interaction between psychopathological symptoms in mood 
and anxiety disorders56, and more recently on schizophrenia52. To date, there are no studies in 
literature that have applied network analysis to the investigation of cognitive impairment in 
depression. 
Consistently with available literature, the results of our study confirmed that patients suffering from 
depression, regardless of longitudinal diagnosis, experience mild cognitive impairment. In fact, in 
our sample, more than 1 out of 2 depressed patients presented with cognitive impairment. 
Confirming the usefulness of MoCA as a screening measure in depression, our result was consistent 
with epidemiological studies reporting a prevalence of cognitive impairment in MDD around 25-
50%57, even though the real prevalence of cognitive alterations in depression is not fully clarified 
yet58,59. In a recent publication, Douglas et al. (2018) found variable prevalences of 14.7-52.9% and 
32.2-64.4% in outpatients with MDD and BD, respectively, in the depressive phase depending on 
the applied definition of cognitive impairment58, and therefore substantially consistent with our 
epidemiological finding. 
The main objective of our study was to highlight the distinctive features of unipolar and bipolar 
depression from a cognitive perspective, as to date evidence on this topic is scarce and contrasting. 
Using classical statistical techniques, we found overlapping patterns of cognitive impairment 
between patients with MDD and BD, quantitatively in terms of severity and qualitatively in terms of 
profile of involved domains. This result is consistent with what has been previously reported by 
several authors: Bearden and colleagues (2006)18, for instance, showed similar patterns of cognitive 
deficits in unipolar and bipolar patients, which did not appear to depend on the clinical status but 
rather related to a common pathophysiological genesis, regarding temporal lobe dysfunction; 
Hermens and co-workers (2010), analyzing the neurocognitive profile of young unipolar and 
bipolar patients, observed overlapping alterations primarily linked to verbal memory impairment15; 
moreover, Daniel et al. (2013) had shown that performance on neurocognitive tests did not 
differentiate patients affected by MDD from those suffering from BD I28. Finally, similar 
neurocognitive alteration patterns have also been reported by Xu et al. (2012)27 and, previously, by 
Sweeney and co-authors (2000)20. 
One strength of the present study lies in the enrollment of unipolar and bipolar patients during the 
acute depressive phase, whereas the samples of the aforementioned studies were heterogeneous and 
constituted by patients in different phases of illness (i.e., depressive/manic and euthymic). 
Furthermore, compared to the present study, most of the mentioned studies were conducted on 
smaller samples. 
Of note, cognitive assessment is generally obtained through the administration of extensive batteries 
of neuropsychological tests, while we characterized it by implementing a cognitive screening test of 
quick and easy administration. Although neuropsychological tests may be preferable in order to 
perform a more comprehensive analysis of a patient's cognitive deficits, in our opinion, the results 
of the present study confirm the usefulness of the MoCA as a screening tool in everyday clinical 
practice, avoiding the risk of confining cognitive assessment solely to research contexts. 
With reference to the main objective of our study, the application of network analysis provided 
additional information, compared to what has been produced with traditional statistical methods, on 
the differential cognitive alterations characteristic of unipolar and bipolar depressed patients. In 
 fact, the results of network analysis suggest the existence of distinct cognitive deficits in unipolar 
versus bipolar depression. Indeed, our findings suggest a wider involvement of the various 
cognitive domains in patients with MDD compared with BD, expressed by a greater density of the 
unipolar depression network compared to that of bipolar depression. A network is a dynamic entity 
that highlights the role of each variable with respect to the others, and in clinical terms a greater 
density means a greater reciprocal influence of the various domains on each other and the 
simultaneous presence of multiple deficits in the single patient. Thus, our results suggest that 
patients with unipolar vs. bipolar depression would present a greater predisposition to have a wider 
range of cognitive deficits, involving multiple domains at the same time. It is important to underline 
that this result does not represent an estimate of the severity of cognitive impairment: in fact, in 
patients with unipolar depression, the individual domains could be quantitatively less compromised 
than in bipolar patients, in which cognitive alterations could be more severe and specific in single 
isolated domains. Consistently with this result, in a direct comparison study, Taylor Tavares and 
colleagues (2007) demonstrated a broader spectrum of cognitive impairment in drug-free patients 
with MDD (including changes in executive functions, set-shifting and working memory) compared 
to bipolar patients32. Furthermore, a more recent study indicated that young patients with bipolar II 
depression had a relatively intact cognitive profile with more isolated and specific deficits 
compared to patients with unipolar depression33. In addition, network metrics provided additional 
information regarding the role of each cognitive domain. For instance, it is interesting to note that 
the three domains with the greatest centrality in the unipolar depression network (memory, attention 
and executive functions) are the same domains for which statistically significant differences 
emerged, compared to healthy controls, in a meta-analysis of 24 clinical trials (784 total patients) 
conducted by Rock et al. (2014)60. In particular, in the network of unipolar depression, memory is 
the cognitive domain with the higher centrality. This means that patients with memory impairment 
more often present other concomitant cognitive changes and that the dysfunction in memory is the 
cognitive symptom that plays a “gluing” role with the other deficits in unipolar patients. Otherwise, 
memory does not seem to play such an important role in BD. This is consistent with the findings of 
a meta-analysis by Xu et al. (2012), in which, during the depressive phase, patients with MDD and 
BD-I had greater impairment in visual memory than BD-II patients, but no difference emerged in 
terms of attention, executive functions and information processing speed27 ⁠. Moreover, in a network-
analytic model, where symptoms are considered in their dynamism and the centrality of a symptom 
is representative of its ability to bring out other symptoms, the fact that memory plays such a central 
role in MDD may align with the evidence that alterations in memory occur in healthy subjects prior 
to the development of full-blown depressive symptomatology61⁠. In our networks, executive 
functions emerged among the cognitive domains with the greatest centrality in both unipolar and 
bipolar depression, though in the latter they represent the cognitive domain with the highest 
betweenness centrality. In clinical terms, the centrality of executive dysfunctions underlines the 
importance that alterations in this specific domain play in determining the global cognitive 
impairment of a bipolar patient. A possible interpretation, in fact, is that a bipolar patient who 
manifests alterations in executive functions would be more at risk of presenting other cognitive 
deficits than a patient presenting with isolated memory deficits. In this specific case, the application 
of the network analysis allows a deeper knowledge of the "dynamic" role of executive functions 
with respect to classic psychometrics. In fact, if on one hand there were no statistically significant 
differences between MDD and BD in terms of alteration of executive functions, the network 
analysis highlighted the most central role played by this cognitive domain in bipolar patients. 
Indeed, executive dysfunctions have been repeatedly described as one of the main cognitive 
impairments in BD62,63⁠, with similar patterns in BD-I and BD-II24⁠, and they significantly contribute 
to the disability associated with the disease. Another difference between MDD and BD emerging 
from the network analysis regarded the more specific role of verbal fluency in bipolar compared to 
unipolar depression.  This is consistent with literature reporting a moderate dysfunction affecting 
verbal fluency in bipolar patients64⁠. In fact, there is evidence that the alteration of verbal fluency 
appears in the early stages of BD and worsens with the progression of mood episodes in BD65⁠, but 
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not in MDD. Still, from network analysis the relevance of attention in both types of depression 
emerged. In fact, attention deficit has been repeatedly described in MDD and BD, both during the 
first episodes of illness29⁠ and in remission66 ⁠. Our sample did not present a significant alteration in 
the domain of attention; however, attention is a moderator of performance in each cognitive test and 
this could further explain its central role in the networks. Finally, the domains of orientation and 
visuospatial skills were the most peripheral in both networks. Clinically, therefore, alterations in 
these domains would emerge only secondarily to alterations in other domains: they would have 
weak influence on other cognitive functions and would not represent useful markers in order to 
distinguish bipolar from unipolar depression. 
Of note, in this study, we evaluated cognitive performance at two time-points: during acute 
depression and at remission. With regard to the course of cognitive impairment between these two 
phases, we found a significant improvement of cognitive function both in unipolar and bipolar 
patients. Anyway, at remission, the mean MoCA score for MDD patients was just above the 
threshold of normality, while it was just below it for BD patients, even though such difference was 
not statistically significant. It is known that in MDD the improvement of cognitive function does 
not proportionally correspond to the improvement of psychopathological symptoms. For this 
reason, remitted patients often present with residual cognitive symptoms beyond the single mood 
episode during euthymia. Moreover, in a previous study by our group67⁠, we reported the presence of 
specific cognitive deficits in adult euthymic patients with BD-I and BD-II. In this perspective, the 
borderline MoCA scores at time of remission (which was defined on the basis of the HDRS and 
HARS scores) might depend on the relatively unstable clinical condition patients were at time of 
evaluation and might reflect the tendency of cognitive symptoms to recover slower than affective 
symptoms after a MDE. 
Reported findings need to be interpreted in light of the following methodological limitations: first 
of all, the enrollment of a control group would have allowed for the comparison of the cognitive 
performance of BD and MDD patients with that of healthy controls. Second, there were different 
treatment patterns between the two groups, due to the naturalistic environment in which the study 
was conducted. Third, the sample size was relatively limited, in particular with regard to 
reproducibility of network analysis. For this reasons, further clinical trials on selected drug-free 
populations are warranted to confirm the evidence emerging from our study. 
 
Conclusion 
In conclusion, during depressive episodes, patients with MDD and BD have similar patterns of 
cognitive impairment in terms of severity and cognitive domains involved, particularly regarding 
executive functions and memory. However, the application of the innovative approach of network 
analysis has allowed to identify some distinctive features between unipolar and bipolar depression: 
in particular, memory deficits seem to have a more specific role in unipolar depression, whereas 
executive functions are altered in both subtypes of mood disorders, though with a more prominent 
role in bipolar depression. Furthermore, attention plays the role of moderator of cognitive function 
in both MDD and BD, and can therefore be interpreted as a state variable associated with 
depression itself, rather than a trait variable peculiar of one single mood disorder. 
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TABLES AND FIGURES 
 
Table 1. List of inclusion and exclusion criteria 
Inclusion criteria 
Male or female gender 
Age>18 
Diagnosis of major depressive episode (MDE) 
Longitudinal diagnosis of major depressive disorder or bipolar disorder I or II, according to DSM-5 criteria 
Exclusion criteria 
Clinically relevant learning or reading disability, dyslexia, illiteracy  
Diagnosis of cognitive disorder 
History of moderate to severe head injury 
Uncontrolled thyroid dysfunction 
Recent alcohol or substance abuse 
Concomitant therapy with high dose anticholinergics  
Concomitant therapy with benzodiazepines at a dosage equal or higher than diazepam 7.5 mg/day 
Electroconvulsive therapy within 6 months 
 
Table 2. Demographic and clinical characteristics of the two groups. 
 MDD BD p 
Sample size 72 37  
Gender, f% 65.3% 70.3% .600 
Age, mean±SD 56.24±14.51 56.89±10.02 .602 
Marital status, % 
Unmarried 15.3% 27.0% .111 
Married 62.5% 59.5% 
Divorced 11.1% 7.3% 
Widow 11.1% 6.2% 
Education, % 
Primary school 9.7% 8.1% .904 
Secondary school 6.4% 21.6% 
High school 41.7% 48.6% 
University 22.2% 21.6% 
Employment status, % 
Unemployed 20.8% 27.0% .744 
Employed 41.7% 32.4% 
Formattato: Interlinea: singola
 Retired 37.5% 40.5% 
Nationality, italian % 93.1% 97.3% .358 
Family history for 
psychiatric disorders, % 
positive 
63.9% 75.7% .212 
Age at onset, mean±SD 34.15±14.94 30.0±12.89 .224 
Duration of untreated illness 
(DUI) in months, mean±SD 
59.81±84.43 63.51±73.33 .074 
Duration of illness in years, 
mean±SD 
22.22±13.59 26.89±12.10 .087 
Psychiatric comorbidities, 
% 
27.6% 13.5% .091 
Comorbidity with personality disorders, % 
None 76.4% 73.0% .463 
Cluster A 1.4% 5.4% 
Cluster B 13.9% 10.8% 
Cluster C 5.6% 2.7% 
Not specified 2.8% 8.1% 
Medical comorbidities, % 
present 
48.6% 40.5% .389 
History of psychosis, 
positive % 
19.4% 27.0% .361 
Hisotry of alcohol abuse, 
positive % 
5.6% 13.5% .153 
History of substance abuse, 
positive % 
11.1% 2.7% .131 
Number of episodes of 
illness, mean±SD 
3.38±1.84 5.57±3.33 .001 
Previous hospitalizations, 
yes %  
22.2% 59.5% <.001 
Previous suicide attempts, 
yes % 
26.4% 45.9% .030 
Time to remission in days, 
m±SD 
77.43±34.85 84.32±37.84 .382 
Current psychopharmacological treatment 
Antidepressants, % 93.1% 75.7% <.001 
Antipsychotics, % 34.7% 59.5% .019 
Mood stabilizers, % 4.2% 40.5% .004 
Benzodiazepines, % 66.7% 56.8% .295 
Depressive and anxious symptomatology 
HDRS score during 
depression, m±SD 
27.35±6.05 26.62±6.45 .756 
HARS score during 
depression, m±SD 
21.61±9.062 18.68±7.32 .115 
HDRS score at remission, 
m±SD 
3.43±2.64 3.68±3.15 .895 
HARS score at remission, 2.41±2.58 2.72±2.66 .512 
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m±SD 
 
Table 3. Mean scores of MoCA single domains during depression. 
 Maximum values MDD BD p 
Memory 5 2.35±1.71 2.32±1.58 .902 
Visuospatial abilities 4 2.81±1.15 2.89±1.27 .514 
Executive functions 4 2.85±1.08 2.70±1.31 .679 
Attention 6 5.40±0.93 5.30±1.24 .823 
Verbal fluency 6 5.01±1.11 5.11±0.94 .862 
Orientation 6 5.81±0.60 5.68±0.63 .126 
MoCA total score 30 24.11±4.04 23.89±3.78 .709 
 
Table 4. Matrix of Spearman’s rho correlation coefficients between the MoCA domains in MDD 
and BD during depression. 
 MEM VA EF ATT VF OR 
MEM - 0.41 0.37 0.28 0.27 0.23 
VA -0.07 - 0.52 0.37 0.42 0.10 
EF 0.43 0.22 - 0.40 0.63 0.29 
ATT 0.54 0.06 0.46 - 0.41 0.18 
VF 0.07 0.21 0.42 0.42 - 0.24 
OR 0.56 0.01 0.48 0.42 0.11 - 
BD: coefficients below diagonal; MDD: coefficients above diagonal. MEM: memory; VA: visuospatial abilities; EF: 
executive functions; ATT: attention; VF: verbal fluency; OR: orientation. 
 
 
Table 5. Top three domains with the highest betweenness centrality and closeness centrality in the 
two groups. 
UNIPOLAR DEPRESSION BIPOLAR DEPRESSION 
Betweenness centrality 
Memory Executive functions 
Executive functions Attention 
Attention Verbal fluency 
Closeness centrality 
Memory Executive functions 
Executive functions Attention 
Attention Memory, visuospatial abilities 
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Figure 1. The unipolar depression network. 
 
 
 
 
 
Figure 2. The bipolar depression network. 
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